Targeted Treatment of Follicular Lymphoma
Follicular lymphoma (FL) is the most common indolent B-cell lymphoma. Advanced stage disease is considered incurable and is characterized by a prolonged relapsing/remitting course. A significant minority have less favorable outcomes, particularly those with transformed or early progressive disease....
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-02-01
|
| Series: | Journal of Personalized Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4426/11/2/152 |
| _version_ | 1797395655847575552 |
|---|---|
| author | Karthik Nath Maher K. Gandhi |
| author_facet | Karthik Nath Maher K. Gandhi |
| author_sort | Karthik Nath |
| collection | DOAJ |
| description | Follicular lymphoma (FL) is the most common indolent B-cell lymphoma. Advanced stage disease is considered incurable and is characterized by a prolonged relapsing/remitting course. A significant minority have less favorable outcomes, particularly those with transformed or early progressive disease. Recent advances in our understanding of the unique genetic and immune biology of FL have led to increasingly potent and precise novel targeted agents, suggesting that a chemotherapy-future may one day be attainable. The current pipeline of new therapeutics is unprecedented. Particularly exciting is that many agents have non-overlapping modes of action, offering potential new combinatorial options and synergies. This review provides up-to-date clinical and mechanistic data on these new therapeutics. Ongoing dedicated attention to basic, translational and clinical research will provide further clarity as to when and how to best use these agents, to improve efficacy without eliciting unnecessary toxicity. |
| first_indexed | 2024-03-09T00:38:39Z |
| format | Article |
| id | doaj.art-976a54937a784a68b966e26ee5941ee6 |
| institution | Directory Open Access Journal |
| issn | 2075-4426 |
| language | English |
| last_indexed | 2024-03-09T00:38:39Z |
| publishDate | 2021-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Personalized Medicine |
| spelling | doaj.art-976a54937a784a68b966e26ee5941ee62023-12-11T17:58:20ZengMDPI AGJournal of Personalized Medicine2075-44262021-02-0111215210.3390/jpm11020152Targeted Treatment of Follicular LymphomaKarthik Nath0Maher K. Gandhi1Mater Research Institute, University of Queensland, Brisbane, QLD 4101, AustraliaMater Research Institute, University of Queensland, Brisbane, QLD 4101, AustraliaFollicular lymphoma (FL) is the most common indolent B-cell lymphoma. Advanced stage disease is considered incurable and is characterized by a prolonged relapsing/remitting course. A significant minority have less favorable outcomes, particularly those with transformed or early progressive disease. Recent advances in our understanding of the unique genetic and immune biology of FL have led to increasingly potent and precise novel targeted agents, suggesting that a chemotherapy-future may one day be attainable. The current pipeline of new therapeutics is unprecedented. Particularly exciting is that many agents have non-overlapping modes of action, offering potential new combinatorial options and synergies. This review provides up-to-date clinical and mechanistic data on these new therapeutics. Ongoing dedicated attention to basic, translational and clinical research will provide further clarity as to when and how to best use these agents, to improve efficacy without eliciting unnecessary toxicity.https://www.mdpi.com/2075-4426/11/2/152follicular lymphomaBruton tyrosine kinase inhibitorsBCL2 inhibitorsanti-CD47antibody-drug conjugatesmonoclonal antibodies |
| spellingShingle | Karthik Nath Maher K. Gandhi Targeted Treatment of Follicular Lymphoma Journal of Personalized Medicine follicular lymphoma Bruton tyrosine kinase inhibitors BCL2 inhibitors anti-CD47 antibody-drug conjugates monoclonal antibodies |
| title | Targeted Treatment of Follicular Lymphoma |
| title_full | Targeted Treatment of Follicular Lymphoma |
| title_fullStr | Targeted Treatment of Follicular Lymphoma |
| title_full_unstemmed | Targeted Treatment of Follicular Lymphoma |
| title_short | Targeted Treatment of Follicular Lymphoma |
| title_sort | targeted treatment of follicular lymphoma |
| topic | follicular lymphoma Bruton tyrosine kinase inhibitors BCL2 inhibitors anti-CD47 antibody-drug conjugates monoclonal antibodies |
| url | https://www.mdpi.com/2075-4426/11/2/152 |
| work_keys_str_mv | AT karthiknath targetedtreatmentoffollicularlymphoma AT maherkgandhi targetedtreatmentoffollicularlymphoma |